Berlin, November 11, 2022 – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for a label extension for Eylea™ (aflibercept) for intravitreal injection 40 mg/mL in a prefilled syringe (PFS) for the treatment of preterm infants with retinopathy of prematurity (ROP…
Read More
About The Author
